FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL

Updated: Aug 23, 2021

NIH - National Cancer Institute - July 29, 2021

On June 30, FDA approved a new form of asparaginase, erwinia chrysanthemi (recombinant)-rywn (Rylaze), which was developed to address the ongoing shortages of Erwinia asparaginase. Rylaze was approved as part of a treatment regimen for children and adults with ALL or lymphoblastic lymphoma (LBL), a rare but aggressive cancer that resembles ALL. Read article>>

4 views0 comments